MxA for differentiating viral and bacterial infections in adults: a prospective, exploratory study.
Antibiotic resistance
Biomarker
Mx1
MxA
Myxovirus resistance protein 1
Viral infection
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
06
07
2022
accepted:
15
01
2023
medline:
3
10
2023
pubmed:
4
2
2023
entrez:
3
2
2023
Statut:
ppublish
Résumé
Inappropriate antibiotic prescription in patients with viral infections contributes to the surge of antibiotic resistance. Viral infections induce the expression of the antiviral protein MxA in monocytes, which is a promising biomarker to differentiate between viral and bacterial diseases. In this prospective, exploratory study, we aimed to determine the diagnostic value of monocyte MxA expression in adults with viral, bacterial or co-infections. We measured monocyte MxA expression using flow cytometry in a cohort of 61 adults with various viral, bacterial and co-infections including patients receiving immunosuppressive therapy. Monocyte MxA expression in virus-infected patients was significantly higher compared to bacterial infections (83.3 [66.8, 109.4] vs. 33.8 [29.3, 47.8] mean fluorescence intensity [MFI]; p < 0.0001) but not co-infections (53.1 [33.9, 88.9] MFI). At a threshold of 62.2 MFI, the area under the ROC curve (AUC) to differentiate between viral and bacterial infections was 0.9, with a sensitivity and specificity of 92.3% and 84.6%, respectively. Immunosuppressive therapy did not affect monocyte MxA expression in virus-infected patients. Our findings corroborate the diagnostic performance of MxA in differentiating viral and bacterial infections but also point to an important caveat of MxA in viral-bacterial co-infections. This study extends previous reports and indicates that MxA is also a useful biomarker in immunocompromised patients.
Identifiants
pubmed: 36737561
doi: 10.1007/s15010-023-01986-0
pii: 10.1007/s15010-023-01986-0
pmc: PMC9897883
doi:
Substances chimiques
Myxovirus Resistance Proteins
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1329-1337Informations de copyright
© 2023. The Author(s).
Références
Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017;177:1308–15. https://doi.org/10.1001/jamainternmed.2017.1938 .
doi: 10.1001/jamainternmed.2017.1938
pubmed: 28604925
pmcid: 5710569
Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13:1057–98. https://doi.org/10.1016/s1473-3099(13)70318-9 .
doi: 10.1016/s1473-3099(13)70318-9
pubmed: 24252483
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–17. https://doi.org/10.1086/421997 .
doi: 10.1086/421997
pubmed: 15307030
ten Oever J, Tromp M, Bleeker-Rovers CP, Joosten LA, Netea MG, Pickkers P, et al. Combination of biomarkers for the discrimination between bacterial and viral lower respiratory tract infections. J Infect. 2012;65:490–5. https://doi.org/10.1016/j.jinf.2012.08.004 .
doi: 10.1016/j.jinf.2012.08.004
pubmed: 22898387
Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70:538–42. https://doi.org/10.1093/cid/ciz545 .
doi: 10.1093/cid/ciz545
pubmed: 31241140
Rhedin S, Lindstrand A, Rotzén-Östlund M, Tolfvenstam T, Ohrmalm L, Rinder MR, et al. Clinical utility of PCR for common viruses in acute respiratory illness. Pediatrics. 2014;133:e538–45. https://doi.org/10.1542/peds.2013-3042 .
doi: 10.1542/peds.2013-3042
pubmed: 24567027
Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8:559–68. https://doi.org/10.1038/nri2314 .
doi: 10.1038/nri2314
pubmed: 18575461
pmcid: 2522268
Engelmann I, Dubos F, Lobert PE, Houssin C, Degas V, Sardet A, et al. Diagnosis of viral infections using myxovirus resistance protein A (MxA). Pediatrics. 2015;135:e985–93. https://doi.org/10.1542/peds.2014-1946 .
doi: 10.1542/peds.2014-1946
pubmed: 25802344
Chieux V, Hober D, Harvey J, Lion G, Lucidarme D, Forzy G, et al. The MxA protein levels in whole blood lysates of patients with various viral infections. J Virol Methods. 1998;70:183–91. https://doi.org/10.1016/s0166-0934(97)00177-8 .
doi: 10.1016/s0166-0934(97)00177-8
pubmed: 9562412
Toivonen L, Schuez-Havupalo L, Rulli M, Ilonen J, Pelkonen J, Melen K, et al. Blood MxA protein as a marker for respiratory virus infections in young children. J Clin Virol. 2015;62:8–13. https://doi.org/10.1016/j.jcv.2014.11.018 .
doi: 10.1016/j.jcv.2014.11.018
pubmed: 25542463
Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, Parekh AD, et al. Diagnostic Accuracy of FebriDx: A rapid test to detect immune responses to viral and bacterial upper respiratory infections. J Clin Med. 2017. https://doi.org/10.3390/jcm6100094 .
doi: 10.3390/jcm6100094
pubmed: 28991170
pmcid: 5664009
Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP point-of-care immunoassay to identify viral and/or bacterial immune response in patients with acute febrile respiratory infection. Eur Clin Respir J. 2015;2:28245. https://doi.org/10.3402/ecrj.v2.28245 .
doi: 10.3402/ecrj.v2.28245
pubmed: 26672961
Piri R, Ivaska L, Yahya M, Toivonen L, Lempainen J, Kataja J, et al. Prevalence of respiratory viruses and antiviral MxA responses in children with febrile urinary tract infection. Eur J Clin Microbiol Infect Dis. 2020;39:1239–44. https://doi.org/10.1007/s10096-020-03836-5 .
doi: 10.1007/s10096-020-03836-5
pubmed: 32048070
pmcid: 7088029
Schrauf C, Kirchberger S, Majdic O, Seyerl M, Zlabinger GJ, Stuhlmeier KM, et al. The ssRNA genome of human rhinovirus induces a type I IFN response but fails to induce maturation in human monocyte-derived dendritic cells. J Immunol. 2009;183:4440–8. https://doi.org/10.4049/jimmunol.0804147 .
doi: 10.4049/jimmunol.0804147
pubmed: 19734213
Puck A, Hopf S, Modak M, Majdic O, Cejka P, Blüml S, et al. The soluble cytoplasmic tail of CD45 (ct-CD45) in human plasma contributes to keep T cells in a quiescent state. Eur J Immunol. 2017;47:193–205. https://doi.org/10.1002/eji.201646405 .
doi: 10.1002/eji.201646405
pubmed: 27718235
Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res. 2011;31:79–87. https://doi.org/10.1089/jir.2010.0076 .
doi: 10.1089/jir.2010.0076
pubmed: 21166595
Ronni T, Melén K, Malygin A, Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J Immunol. 1993;150:1715–26.
doi: 10.4049/jimmunol.150.5.1715
pubmed: 7679692
Ivaska L, Niemelä J, Lempainen J, Österback R, Waris M, Vuorinen T, et al. Aetiology of febrile pharyngitis in children: Potential of myxovirus resistance protein A (MxA) as a biomarker of viral infection. J Infect. 2017;74:385–92. https://doi.org/10.1016/j.jinf.2017.01.002 .
doi: 10.1016/j.jinf.2017.01.002
pubmed: 28077283
pmcid: 7127312
Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol. 2010;10:514–26. https://doi.org/10.1038/nri2802 .
doi: 10.1038/nri2802
pubmed: 20577268
pmcid: 3899649
Lehtinen O, Broman N, Waris M, Vuorinen T, Peltola V, Löyttyniemi E, et al. Association of human myxovirus resistance protein A with severity of COVID-19. BMC Infect Dis. 2022;22:755. https://doi.org/10.1186/s12879-022-07753-0 .
doi: 10.1186/s12879-022-07753-0
pubmed: 36171547
pmcid: 9517979
Airò P, Ghidini C, Zanotti C, Scarsi M, Cattaneo R, Caimi L, et al. Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis. J Rheumatol. 2008;35:2192–200. https://doi.org/10.3899/jrheum.080418 .
doi: 10.3899/jrheum.080418
pubmed: 18843779
Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56:1662–75. https://doi.org/10.1093/rheumatology/kew431 .
doi: 10.1093/rheumatology/kew431
pubmed: 28122959
Yoshimasu T, Manabe A, Ebihara Y, Tanaka R, Ooi J, Iseki T, et al. MxA expression in patients with viral infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32:313–6. https://doi.org/10.1038/sj.bmt.1704128 .
doi: 10.1038/sj.bmt.1704128
pubmed: 12858204
Koskenvuo MM, Halminen M, Blomqvist M, Vainionpää R, Ilonen J, Julkunen I, et al. Expression of MxA protein in blood lymphocytes of children receiving anticancer chemotherapy. Pediatr Hematol Oncol. 2006;23:649–60. https://doi.org/10.1080/08880010600956863 .
doi: 10.1080/08880010600956863
pubmed: 17065141
Tong-Minh K, van Hooijdonk S, Versnel MA, van Helden-Meeuwsen CG, van Hagen PM, van Gorp ECM, et al. Blood myxovirus resistance protein-1 measurement in the diagnostic work-up of suspected COVID-19 infection in the emergency department. Immun Inflamm Dis. 2022. https://doi.org/10.1002/iid3.609 .
doi: 10.1002/iid3.609
pubmed: 35349755
pmcid: 8962640
Shapiro NI, Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Annals Med. 2018;50:420–9. https://doi.org/10.1080/07853890.2018.1474002 .
doi: 10.1080/07853890.2018.1474002
Shirley M. FebriDx(®): A rapid diagnostic test for differentiating bacterial and viral aetiologies in acute respiratory infections. Mol Diagn Ther. 2019;23:803–9. https://doi.org/10.1007/s40291-019-00433-x .
doi: 10.1007/s40291-019-00433-x
pubmed: 31691924
pmcid: 7099706
Houston H, Deas G, Naik S, Shah K. Utility of the FebriDx point-of-care assay in supporting a triage algorithm for medical admissions with possible COVID-19: an observational cohort study. BMJ. 2021;11: e049179. https://doi.org/10.1136/bmjopen-2021-049179 .
doi: 10.1136/bmjopen-2021-049179
Clark TW, Brendish NJ, Poole S, Naidu VV, Mansbridge C, Norton N, et al. Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19. J Infect. 2020;81:607–13. https://doi.org/10.1016/j.jinf.2020.06.051 .
doi: 10.1016/j.jinf.2020.06.051
pubmed: 32579983
pmcid: 7306108
Karim N, Ashraf MZ, Naeem M, Anwar T, Aung H, Mallik S, et al. Utility of the FebriDx point-of-care test for rapid triage and identification of possible coronavirus disease 2019 (COVID-19). Int J Clin Pract. 2021;75: e13702. https://doi.org/10.1111/ijcp.13702 .
doi: 10.1111/ijcp.13702
pubmed: 32896946